News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Israeli Patent For Treatment Of Dry Eye Syndrome


2/24/2014 9:11:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that it has received an Israeli patent for the treatment of Dry Eye Syndrome using Thymosin beta 4 (Tß4) and various fragments of Tß4, as well as other analogues and derivatives. The patent will expire in 2026.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES